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Summary
Background: The installation of drug databases on
personal digital assistants (PDAs) allows for rapid
detection of adverse drug interactions at the point
of care.
Aim: To test the ability of a drug interaction database
(ePocrates RX) to correctly identify clinically sig-
nificant adverse drug interactions in an out-patient
setting.
Design: Retrospective file review of 1801 drug
prescriptions in out-patients consulting a medical
walk-in clinic.
Methods: Each prescription was assessed indepen-
dently by a clinical pharmacologist using drug-drug
interaction compendia, and by a general internist
using the drug interaction database. Discrepant
results were systematically reviewed by both, using
published literature, and a consensus was then
reached. This consensus was used as the criterion
against which the PDA drug interaction database
was judged.
Results: The prevalence of potential adverse drug
interactions was 23%. When compared to the
opinion of the clinical pharmacologist and drug-
drug interaction compedia, the sensitivity of the
drug interaction database to correctly identify
clinically relevant adverse drug interactions was
81% (95%CI 77%–85%) and the specificity was
88% (95%CI 86–89%). The positive predictive value
was poor (67%, 95%CI 62%–71%) but the negative
predictive value was excellent (94%, 95%CI
92%–95%).
Discussion: The database was an efficient tool for
rapidly checking for potentially harmful drug inter-
action, but also flagged up several clinically non-
significant interactions. When used appropriately,
this drug interaction database could help physicians
decrease prescription error, by ruling out the risk
of clinically relevant adverse drug interactions for
newly prescribed drugs, and thereby increase
patient safety.
Introduction
Drug prescription is the most common therapeutic
act in primary care. Physicians need to be aware of
adverse drug events (ADEs), as they are common,
under-reported, result in dissatisfaction with care
and decreased quality of life, and also account for
frequent visits to the Emergency Department (ED).1,2
Awareness of ADEs is becoming increasingly
important because of its medical and eco-
nomical consequences, especially as a considerable
percentage of all ADE-related visits and ADE-related
admissions are considered to be avoidable.3–7
A prospective observational study reported that
28% of ED visits were due to medication-related
problems, of which 70% were felt to be preven-
table.5 A review of 15 studies conducted worldwide
found a median drug-related hospital admission rate
of 7%.8 Among the elderly, this figure can rise to
30%.9 In in-patient settings, the frequency of ADEs
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has been estimated to vary between 7% and 20%.10
In out-patient care, despite the large proportion of
prescription drugs used, the incidence of ADEs has
not been well documented. One prospective cohort
study suggested that it may be a common problem
involving up to 25% of patients, of which 23% were
estimated as preventable.1 One third of these
preventable errors could have been detected by an
advanced computerized system.
Adverse drug interactions (ADIs) are a subset of
ADEs that is entirely preventable. Potential risk
factors for the development of ADIs include poly-
pharmacy, multiple morbidities, and certain drug
specificities (for example, pharmacokinetic proper-
ties such as important first-pass metabolism, high
transporters or enzyme affinity, high potencies,
narrow therapeutic range or low therapeutic
index). The rates of potential drug interactions for
patients receiving two or more drugs can vary from
2%11 to 42%,12 with the proportion of visits to the
ED or hospital admissions due to ADIs varying from
1 to 4%.13,14 Among out-patients, the proportion
of ADEs caused by ADIs is estimated to be 3%.15 In
a retrospective review of prescription data in a
primary health-care centre, the incidence of poten-
tial interactions was 12%, rising to 22% for elderly
patients.11
Systematic screening for drug interactions can be
fastidious and time-consuming in the rapidly grow-
ing field of therapeutics.16 Computer databases have
been shown to limit prescription errors in both
hospitalized patients and dispensing pharmacies,
and have been adopted by several hospitals and
pharmacies.17,18 However, the efficacy of this
approach in out-patient settings is less well docu-
mented. A prospective study with Australian general
practitioners (GPs) working with out-patients
showed that when a change was proposed by a
pharmacist, 54% of GPs followed the advice, and
the action taken had a positive outcome in 71% of
cases.19
In recent years, personal digital assistants (PDAs)
have become increasingly popular among health-
care professionals.20–22 Sufficient portable storage
capacity allows for easy use of even large drug
databases, potentially bringing point-of-care tech-
nology and prescription safety to out-patient set-
tings. ePocrates RX is a free-of-charge core drug
information database that was first introduced in
1999 and can be easily installed on a PDA. It allows
for the simultaneous and expeditious checking of
ADIs between up to 30 drugs.20 Comparison of
different drug information databases designed for
PDAs to detect ADIs have shown that they vary in
completeness and ease of use.23–26 In these studies,
the performance of ePocrates RX with respect to
other drug databases in detecting drug interactions
varied from intermediate to very good. Physicians
perceived its use as an improvement in their clinical
behaviour (better drug decisions), practice efficiency
(time saved) and patient care.27 A recent study
conducted on clerkship students found that they
rated drug databases on PDAs (ePocrates RX) as
being, along with the Griffiths’ five minute Consult,
the most useful medical software, and their satisfac-
tion correlated with the documented use of these
programs.22 This is currently the only core drug
database available for PDAs that is both free of
charge and regularly updated.26
We tested the ability of this drug interaction
database to correctly identify clinically significant
ADIs in prescriptions written out for patients
consulting a medical out-patient clinic and to
document the prevalence of clinically significant
ADIs in this setting.
Methods
Data collection
Prescription data for 591 consecutive patients
consulting the medical out-patient clinic of the
Geneva University Hospitals over a 2 week period
were retrieved from the medical file records. Patient
drug profiles, including drugs that the patient was
currently taking, as well as those prescribed during
the visit, were individually entered into a database.
Information regarding the symptoms for which the
patient consulted (e.g. cough) and the diagnosis
made by the physician during the consultation (e.g.
sinusitis) were also recorded. Drugs were classified
according to the Anatomical Therapeutic Chemical
Classification Index. For each consultation, a double
assessment was performed. First, a clinical pharma-
cologist (JD) evaluated whether the different pre-
scribed drugs could result in a clinically significant
ADI, basing his decision on drug-drug interaction
compendia that are considered as reference text-
books by clinical pharmacologists.28–30 Second, a
board-certified general internist (MFD) entered all
the prescribed drugs into the PDA drug interaction
database, and noted when a warning message
flagged an ADI. When the drug used was not
found in ePocrates RX, a drug with a similar
pharmacological profile was used instead. Certain
drugs (e.g. moclobemide, a monoamine inhibitor
anti-depressant drug) could therefore not be entered
into the drug interaction program. The assessments
were performed on separate databases that were
then merged to identify discrepancies. Discrepant
results were systematically reviewed by both
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assessors using published literature, and a consensus
was then reached. This consensus was used as the
criterion against which the PDA drug interaction
database was judged.
ADIs were classified into two broad categories
according to the drug interaction mechanisms that
were involved: pharmacokinetic and pharmacody-
namic. Pharmacodynamic interactions were further
divided into synergistic (e.g. the risk of serotonin
syndrome when using tramadol and SSRIs such as
sertraline) and antagonistic interactions (e.g. using
an antihypertensive treatment along with a vaso-
constrictor such as phenylephrine, largely pre-
scribed for a common cold).
Statistical analysis
The statistical analyses were performed at two
different levels. First, we computed descriptive
statistics at the patient level to give general
information about drug prescriptions and overall
ADI prevalence. Then, to determine the ability of the
drug interaction database to detect clinically sig-
nificant ADI, each drug prescription was analysed
separately to determine whether it could be
involved in a significant ADI. The level of accuracy
of the drug interaction database was compared to
the consensus, as previously defined. These data
were used to compute the sensitivity, specificity,
positive and negative predictive values for the PDA
drug interaction database. We also computed
95%CIs around these estimates.31,32
Results
The mean age of patients included in this review
was 39 years (SD 17; quartiles 26–35–48; min 16,
max 94) and 54% (n¼319) were female. For 59% of
the patients (346/591), a pre-existing drug had been
documented in the medical file (1.4 pre-existing
drug treatments/patient; SD 1.7; quartiles 0–1–2;
min 0; max 10). New drugs had been prescribed in
78% (460/591) of consultations (1.6 drugs new drug
treatment/patient; SD 1.3; quartiles 1–2–2; min 0;
max 8).
In 23% (135/591) of the consultations, a poten-
tially clinically significant ADI was identified by the
consensus. Synergistic pharmacodynamic interac-
tions were found in 84% (114/135), antagonistic
pharmacodynamic interactions in 20% (27/135) and
pharmacokinetic interactions in 48% (65/135), of
which 88% (57/65) were due to inhibition or
induction of hepatic cytochromes P-450 by drugs
(e.g. inhibition of cyclosporine metabolism by
ketoconazole). Concerning the class of medication,
anti-inflammatory and anti-rheumatic products were
involved in 62% of ADIs (84/135), mainly because
of the risk of acute renal insufficiency or of arterial
hypertension when administered concomitantly
with antihypertensive drugs or nasal preparations
containing sympathicomimetic agents. Psychotropes
were also frequently involved (19%, 26/135), with
the risk of excessive sedation (e.g. prescription of
two neuroleptics or concomitant prescription of a
neuroleptic with a benzodiazepine or a SSRI).
Cardiovascular drugs were involved in 16% (22/
135) of the cases.
Among the 1801 drug prescriptions, 418 were
identified as having potentially clinically significant
ADIs (23%). The PDA drug interaction database
identified 339 ADIs correctly (81%), over-detected
170 situations, missed 79 situations, and excluded
ADIs in 1213 situations (Tables 1–3). The sensitivity
and specificity were 81% (95%CI 77%–85%) and
88% (95%CI 86%–89%), respectively. For this
prevalence, the positive predictive value was poor
(67%, 95%CI 62%–71%), but the negative predic-
tive value was excellent (94%, 95%CI 92%–95%).
Discussion
The PDA drug interaction database correctly identi-
fied 81% of ADIs and correctly excluded 88%. We
are not aware of previous reports using this drug
interaction database with real patient profiles in an
out-patient setting, but Robinson and Burk found
better values for sensitivity and specificity (100%
and 88% respectively)24 using six hypothetical
patient profiles, while Perkins et al. found sensitivity
and specificity to be 590%,26 also using six
simulated patient profiles. Our use of real patient
profiles seems more likely to identify the limitations
of such drug interaction databases.
The rather low sensitivity of the PDA drug
interaction database was partly due to its inability
to identify several ADIs, such as concomitant use of
different non-steroidal anti-inflammatory drugs or
use of NSAIDs and phenylephrine (Table 3). The
poor positive predictive value was largely explained
by a high prevalence of concomitant prescription of
anti-inflammatory agents (NSAIDs) and acetamino-
phen, a situation considered to be an ADI by the
PDA drug interaction database, and which repre-
sented over half the cases of over-detection
(Table 2). NSAIDs are known for their nephrotoxicity,
due largely to decreased prostaglandin production
(cyclo-oxygenase-2 inhibition), although other
mechanisms such as acute interstitial nephritis,
nephrotic syndrome, or papillary necrosis have also
been described. The acetaminophen precursor phe-
nacetin has been strongly associated with analgesic
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nephropathy.33 However, the suspected nephrotoxi-
city of acetaminophen is largely based on a single
case-control study of patients with end-stage renal
disease, which showed an association between the
cumulative intake of acetaminophen and the relative
risk of renal failure. The risk associated with
acetaminophen use could have been biased; as
patients with renal disease are more likely to have
Table 1 Adverse drug interactions correctly identified
(n¼339) by a personal digital assistant interaction
database (ePocrates RX) in 1801 drug prescriptions
n % Interaction
type
NSAIDs and 2nd NSAID
e.g. aspirin, mefenamic acid)
51 15.0 PD
NSAIDs and anti-hypertensive
drugs (e.g. ACE inhibitors
and sartans, diuretics,
beta-blockers)
32 9.4 PD
NSAIDs and prednisone 15 4.4 PD
NSAIDs and quinolones 12 3.5 PD
NSAIDs and COX-2 inhibitors 8 2.4 PD
NSAIDs and warfarin/heparin 5 1.5 PD
NSAIDs and phenylephrine* 2 0.6 PD
NSAIDs and lithium 2 0.6 PD
NSAIDs and methotrexate 1 0.3 PD
Piroxicam and formoterol* 1 0.3 PD
Benzodiazepines and 2nd
benzodiazepines
32 9.4 PD
Benzodiazepines and
anti-psychotic
16 4.7 PD
Benzodiazepines and analgesics
(e. g. codeine, morphine,
tramadol)
12 3.6 PD
Benzodiazepines and anti-hista-
mine (e.g. cetirizine)
10 3.0 PD
Benzodiazepines and anti-
depressant (e.g. paroxetine,
mirtazapine, amitryptiline)
6 1.8 PD
Flurazepam and clarithromycine 4 1.2 PK
Carbamazepine and buspirone 2 0.6 PK
Anti-psychotic and 2nd anti-
psychotic
8 2.4 PD
Anti-psychotic with anti-depres-
sant (e.g. trimipramine, ven-
lafaxine, paroxetine)
6 1.8 PD
Anti-psychotic and anti-
histamine
2 0.6 PD
Anti-psychotic and nitrates 2 0.6 PD
Anti-psychotic and methadone 1 0.3 PDþPK
Anti-psychotic and
metoclopramide
1 0.3 PD
Anti-psychotic and lithium 1 0.3 PD
Tizanidine and benzodiazepine/
anti-depressant/
anti-psychotic
11 3.3 PD
Tizanidine and enalapril 1 0.3 PD
ACE inhibitors/sartan and loop
diuretics
10 3.0 PD
ACE inhibitors and
spironolactone
2 0.6 PD
Warfarin and low molecular
weight heparin
9 2.7 PD
Warfarin and simvastatin 2 0.6 PK
(continued)
Table 1 Continued
n % Interaction
type
Metoclopramide and
scopolamine
8 2.4 PD
Antihistamine and 2nd antihis-
tamine (e.g. cetirizine and
hydroxyzine)
6 1.8 PD
Valproic acid and
clarithromycine
4 1.2 PK
Valproic acid and mefloquine 2 0.6 PK
Valproic acid and mirtazapine 1 0.3 PDþPK
Valproic acid and warfarin 1 0.3 PK
Iron and proton-pump inhibitors 4 1.2 PK
Amiodarone and warfarin 3 0.9 PK
Amiodarone and digoxine 1 0.3 PDþPK
Amiodarone and beta-blockers 1 0.3 PD
Amiodarone and sulfonylurea 1 0.3 PK
Amiodarone and simvastatin 1 0.3 PD
Beta-blockers and sulfonylurea 3 0.9 PD
Beta-blockers and simvastatin 1 0.3 PK
Codeine and antihistamine
(e.g. clemastine)
3 0.9 PD
Codeine and tramadol 3 0.9 PD
Sulfonylurea and 2nd
sulfonylurea
2 0.6 PD
Digoxine and thiazide diuretic 2 0.6 PD
Fluvoxamine and thioridazine 2 0.6 PDþPK
Quinolones and cisapride 2 0.6 PD
Phenylephrine and anti-hyper-
tensive drugs (beta-blockers)
2 0.6 PD
Phenylephrine and 2nd pheny-
lephrine (nasal)*
2 0.6 PD
Phenylephrine and ergotamine 1 0.3 PD
Hydrocholrothiazide and
furosemide
2 0.6 PD
Tramadol and venlafaxine 2 0.6 PD
Verapamil and simvastatin 3 0.9 PK
Verapamil and nitrates 2 0.6 PD
Verapamil and danazol* 1 0.3 PK
Verapamil and theophylline 1 0.3 PK
Others 5 1.5 Varied
ACE, angiotensin-converting enzyme; NSAID, non-steroidal
anti-inflammatory drug; PK, pharmaco-kinetic interaction;
PD, pharmaco-dynamic interaction. *Interaction no
longer listed in the drug interaction database.
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symptoms requiring analgesics, they were probably
advised to use acetaminophen preferentially over
aspirin or NSAIDs.34 The increased use of acetami-
nophen could thus be a consequence of end-stage
renal disease and not necessarily its cause. Because
of the retrospective nature of this study, a definite
temporal link could not be made. Furthermore,
acetaminophen is not known to inhibit cyclo-
oxygenase 2 at therapeutic doses (3–4 g/day) and
the renal toxicity of chronic monotherapy with
acetaminophen, a primary metabolite of phenacetin,
remains unproven. So far there are no clinical trials
or case reports of ADIs when using these two drugs
together, despite the wide use of NSAIDs and
acetaminophen for pain relief. For these reasons,
we did not consider concomitant use of NSAIDs and
acetaminophen as an ADI.
Drawbacks perceived when using ePocrates Rx
were the absence of mechanism of the interaction
for some drug combinations, the level of evidence
(theoretical, case reports versus clinical trials),
Table 2 Adverse drug interactions incorrectly detected
(n¼ 170) by a personal digital assistant drug interaction
database (ePocrates RX) in 1801 drug prescriptions
n %
Acetaminophen and NSAIDs 95 55.9
Acetaminophen and warfarin 2 1.2
Tizanidine and tramadol 9 5.3
Tizanidine and codeine 2 1.2
Tizanidine and anti-histamine* 1 0.6
Oral contraception and antibiotics 9 5.3
Oral contraception and tizanidine 4 2.4
Sulfonylurea (e.g. glimepiride)
and diuretics
7 4.1
Sulfonylurea and metformin 2 1.2
Sulfonylurea and isoniazid 2 1.2
Glimepiride and aspirin* 2 1.2
Metformin and valacyclovir* 2 1.2
Metformin and insulin 1 0.6
Metformin and beta-blockers 1 0.6
Metoclopramide and benzodiazepines 5 2.9
Prednisone and beta-2 bronchodilators* 5 2.9
Beta-2 bronchodilators and diuretics 2 1.2
Ferrous sulfate and thyroid hormones 2 1.2
Allopurinol and amoxicilline 2 1.2
Proton pump inhibitor and pancrelipase 2 1.2
Prednisone and oestrogen 1 0.6
Trimethoprim/sulfamethoxazole
and mycophenolate mofetil
1 0.6
Fixed drug combination
(e.g. valsartan and hydrochlorothiazide)
5 3
NSAID, non-steroidal anti-inflammatory drug.
*Interaction currently no longer mistakenly listed in the
drug interaction database.
Table 3 Adverse drug interactions missed (n¼ 79) by a
personal digital assistant drug interaction database
(ePocrates RX) in 1801 drug prescriptions
n % Interaction
type
NSAID and a 2nd NSAID
(e.g. ibuprofen with
diclofenac)
10 12.7 PDþPK
NSAIDs and phenylephrine 8 10.1 PD
NSAIDs and salbutamol 2 2.5 PD
NSAIDs and venlafaxine 2 2.5 PD
Aspirin and ibuprofen* 2 2.5 PD
Aspirin and prednisone 1 1.3 PD
Oral and nasal phenylephrine 8 10.1 PD
Hypotensive drugs
(e.g. nifedipine) and NSAIDs
3 3.8 PD
Hypotensive drugs
(e.g. enalapril) and
phenylephrine
1 1.3 PD
Hypotensive drugs
(e.g. enalapril, nifedipine) and
prednisone
3 3.8 PD
Hypotensive drugs (e.g. sartans,
beta-blockers) and tizanidine
3 4.8 PD
Enalapril/captopirl and losartan 2 2.5 PD
Moclobemide (MAO inhibitor)
and tryptan
1 1.3 PD
Moclobemide (MAO inhibitor)
and ethylephrine
2 2.5 PD
Isradipine (calcium channel
blocker) and tacrolimus
2 2.5 PK
Beta-blocker and codeine 1 1.3 PK
Beta-blocker and simvastatin 3 3.8 PK
Simvastatin and SSRI 3 3.8 PK
Simvastatin and cyclosporine* 1 1.3 PK
Anti-histamine and 2nd
anti-histamine (e.g.
fexofenadine, loratidine)
1 1.3 PD
Anti-histamine
(e.g. fexofenadine, loratadine)
and codeine
4 5.1 PK
Loperamide and codeine 2 2.5 PD
Loperamide and ciprofloxacine 1 1.3 PK
Benzodiazepines and SSRI 3 3.8 PD
Codeine and flunarizine 2 2.5 PD
Ciprofloxacine and
benzodiazepines
1 1.3 PK
Mefloquine and nifedipine 1 1.3 PK
Paroxetine and anti-psychotics
(e.g. olanzapine)
1 1.3 PDþ PK
Tramadol and efavirenz 1 1.3 PK
Warfarin and chlordiazepoxide 1 1.3 PK
Others 2 2.5 Varied
MAO inhibitors, monoamine oxidase inhibitors; SSRI,
selective serotonin reuptake inhibitor; NSAID, non-
steroidal anti-inflammatory drug; PK, pharmaco-kinetic
interaction; PD, pharmaco-dynamic interaction.
*Interaction now added to the drug interaction database.
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and alternative therapeutic options. Also, some
drugs commonly used outside the US cannot be
found in the drug database. However, improve-
ments are being continually made, and drug
information is regularly updated. Thus some ADIs
that were under-detected at the time of the study are
now correctly identified (e.g. aspirin and ibuprofen),
and concomitant use of certain drugs is no longer
considered an ADI (e.g. glimepiride and aspirin).
These situations have been marked with an asterisk
in the Tables.
We found an incidence of potential clinical
adverse drug interactions of 23% in our setting.
This high estimate is probably because data were
collected during the winter season, when a large
number of prescriptions contained a combination of
NSAIDs with systemic and/or topical vasoconstric-
tors. Among other limitations, the use of a single
pharmacologist could be perceived as a major
weakness. However we did not base our ’gold
standard’ only on his single opinion, as all
discrepant results were systematically reviewed.
We believe that this process limited the risk of bias
of having a single expert opinion.
Conclusions
Adverse drug interactions are a preventable subset
of adverse drug events. Identifying them has become
a challenge for general practitioners, as the speedy
retrieval of pertinent drug information is often
difficult, as is also the memorizing of all possible
interactions. With the advent of PDAs, and their
growing popularity among healthcare professionals,
point-of-care technology can be extended to an out-
patient setting. Use of drug databases allows for
expeditious retrieval of relevant information, and
may thereby limit potential prescription errors. The
PDA drug interaction database we used had an
excellent negative predictive value, allowing for a
safer prescription of drugs when no ADIs were
detected.
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